Melanoma Think Tank

CME

Think Tank on Melanoma: Optimizing Therapy for Patients in an Evolving Treatment Landscape

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 02, 2023

Expiration: August 01, 2024

Evan J. Lipson
Evan J. Lipson, MD

Activity

Progress
1
Course Completed

Introduction

In this module, Evan Lipson, MD, reviews the latest data on melanoma therapy and offers expert guidance to optimize therapy for patients with melanoma.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails within the activity.

An additional component of this program is an Interactive Treatment Decision Tool where you can enter an individual patient’s disease characteristics and see recommendations from 5 experts in melanoma. Several patient cases are featured throughout this module.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with melanoma do you provide care for in a typical month?

In your current practice, what therapy would you recommend for an otherwise healthy asymptomatic 58-year-old patient with newly diagnosed stage IV BRAFV600E-mutant melanoma with no brain metastases and the goal of maximizing progression-free survival (PFS)?

For a patient receiving nivolumab plus ipilimumab for stage IV melanoma who develops grade 2 diarrhea, in addition to close monitoring, which of the following proactive strategies would you use to manage this adverse event and decrease the possibility of worsening?

For a patient with resected stage IIIC BRAF wild-type melanoma, which of the following FDA-approved therapies would you recommend in the adjuvant setting?

Lifileucel is a tumor-infiltrating lymphocyte (TIL) therapy that was examined in a phase II trial of patients with previously treated advanced melanoma refractory to anti‒PD-1 therapy. Which of the following statements accurately represents the efficacy findings from this trial?